61 results on '"Winkler, Thomas"'
Search Results
2. Expansion of Plasmablasts at Day 90 after Allogeneic Stem Cell Transplantation Predict Chronic Gvhd
3. Function-Preserving Single Amino Acid Substitutions Shield Hematopoietic Stem and Progenitor Cells from CD117 Targeted Immunotherapy In Vivo
4. Studies of a mosaic patient with DBA and chimeric mice reveal erythroid cell–extrinsic contributions to erythropoiesis
5. Prospective Phase I/II Study of Eltrombopag for the Treatment of Bone Marrow Failure in Fanconi Anemia
6. NIMBLE: A Phase I/II Study of AZD0466 Monotherapy or in Combination in Patients with Advanced Hematological Malignancies
7. Molecular Characterization of Clinical Response and Relapse in Patients with IDH1-Mutant Newly Diagnosed Acute Myeloid Leukemia Treated with Ivosidenib and Azacitidine
8. Long-Term Eltrombopag for Bone Marrow Failure Depletes Total Body Iron
9. A Diamond-Blackfan Anemia Patient's Response to Eltrombopag and Genomic Analysis in Different Lineages
10. Ivosidenib Improves Overall Survival Relative to Standard Therapies in Relapsed or Refractory Mutant IDH1 AML: Results from Matched Comparisons to Historical Controls
11. Eltrombopag for patients with moderate aplastic anemia or uni-lineage cytopenias
12. Phase II Study of Eltrombopag in Subjects with Fanconi Anemia
13. Ivosidenib (AG-120) in Patients with IDH1-Mutant Relapsed/Refractory Myelodysplastic Syndrome: Updated Enrollment of a Phase 1 Dose Escalation and Expansion Study
14. High Rate of IDH1 Mutation Clearance and Measurable Residual Disease Negativity in Patients with IDH1-Mutant Newly Diagnosed Acute Myeloid Leukemia Treated with Ivosidenib (AG-120) and Azacitidine
15. AGILE: A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of Ivosidenib in Combination with Azacitidine in Adult Patients with Previously Untreated Acute Myeloid Leukemia with an IDH1 Mutation
16. Treatment optimization and genomic outcomes in refractory severe aplastic anemia treated with eltrombopag
17. Eltrombopag maintains human hematopoietic stem and progenitor cells under inflammatory conditions mediated by IFN-γ
18. GATA2 deficiency and human hematopoietic development modeled using induced pluripotent stem cells
19. Eltrombopag for Moderate Aplastic Anemia and Unilineage Cytopenias: Dosing, Long-Term Follow-up, Clonal Evolution and Somatic Mutation Profiling
20. Eltrombopag Improves Hematopoiesis in Patients with Low to Intermediate-2 Risk Myelodysplastic Syndrome (MDS)
21. Vaccination after Allogenic Stem Cell Transplantation: Diminished Memory B Cell Response and High Number of Spontaneously IgG Secreting Plasmablasts
22. Single Cell Transcriptome Analysis of GATA2 Deficiency in Hematopoiesis Modeled with Induced Pluripotent Stem Cells
23. Eltrombopag mobilizes iron in patients with aplastic anemia
24. Eltrombopag for Refractory Severe Aplastic Anemia: Dosing Regimens, Long-Term Follow-up, Clonal Evolution and Somatic Mutation Profiling
25. Acquired somatic mutations in PNH reveal long-term maintenance of adaptive NK cells independent of HSPCs
26. Adaptive NK cells can persist in patients with GATA2 mutation depleted of stem and progenitor cells
27. Nontransplant therapy for bone marrow failure
28. Successful Treatment of a Diamond-Blackfan Anemia (DBA) Patient with Eltrombopag
29. Adoptive Transfer of Purified Donor-B-Lymphocytes after Allogeneic Stem Cell Transplantation: Results from a Phase I/IIa Clinical Trial
30. Myeloid Neoplasm Gene Somatic Mutations in Patients with Severe Aplastic Anemia Treated with Eltrombopag and Standard Immunosuppression
31. Insights into Clonal Relationships of Putative Adaptive Natural Killer Cells (NK) in Humans, Via Mapping of Somatic Piga Mutations in Patients with Paroxysmal Nocturna Hemoglobinuria (PNH)
32. Eltrombopag Added to Standard Immunosuppression for Aplastic Anemia Accelerates Count Recovery and Increases Response Rates
33. Persistent Elevation of Plasma Thrombopoietin Levels in Severe Aplastic Anemia, Even with Hematologic Recovery
34. More Efficient Generation of β-Globin-Expressing Erythroid Cells Using Stromal Cell-Derived Induced Pluripotent Stem Cells
35. Specific Impaired CD56+ NK Cell Development in GATA2 Deficiency As Revealed By Ex Vivo NK Expansion
36. β-Globin-Expressing Definitive Erythroid Progenitor Cells Generated from Embryonic and Induced Pluripotent Stem Cell-Derived Sacs
37. Engraftment of donor cells with germ-line integration of HHV6 mimics HHV6 reactivation following cord blood/haplo transplantation
38. Regulatory T Cells Preserve Anti-Viral Immunity While Preventing Lethal Graft-Versus-Host Disease
39. Generation Of Mature Erythroid Cells From Human Embryonic Stem Cell Derived Sacs and Optimization Of Erythroid Cell Generation
40. A Platform Minigene AAVS1 Targeted Safe Harbor Approach For Genetic Correction Of iPSC Derived From Patients With Each Of The 5 Genetic Forms Of Chronic Granulomatous Disease
41. GMP-Grade Generation of B-Lymphocytes for Adoptive Immunotherapy in Patients After Allogeneic Stem Cell Transplantation
42. Development of an Inducible Caspase-9 Safety Switch for Pluripotent Stem Cell Based Therapies
43. Telomere Dynamics in Pluripotent Stem Cells Derived From Patients with Telomere Diseases
44. BCL2A1 Is a Survival and Immortalization Factor for Primitive Hematopoietic Cells.
45. Analysis of Viral Integration Sites in Human Induced Pluripotent Stem Cells.
46. Protection from CMV infection in immunodeficient hosts by adoptive transfer of memory B cells
47. Memory B Cells Protect from CMV Infection in the Absence of T Cells.
48. PBSCT Similar to BMT Allows Active B-Lymphopoiesis Unless Severe GVHD Occurs.
49. Specific inhibition of bcr-abl gene expression by small interfering RNA
50. Functional comparison of thymic B cells and dendritic cells in vivo
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.